

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

SECRETARY OF THE SENATE
07 MAR 30 AM 9:20

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant name Organization Novartis			
2. Address <input type="checkbox"/> Check if different than previously reported Address1 701 Pennsylvania Ave. NW Suite 725 City Washington State DC Zip Code 20004 Country US			
3. Principal place of business (if different than line 2) City _____ State _____ Zip Code _____ Country _____ State/Zip or Country			
4a. Contact Name Prefix Full Name Mrs. Andrea McCabe		b. Telephone number 202-638-7429	c. E-mail andrea.mccabe@novartis.com
7. Client Name <input checked="" type="checkbox"/> Self Novartis			5. Senate ID # 9204-1 6. House ID # 335890

TYPE OF REPORT 8. Year 2006 Midyear (January 1-June 30) OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇒ Termination Date _____ 11. No Lobbying Act

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇒ \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇒ \$ <u>2,346,285</u></p> <p>14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definition</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Revenue Code</p>
--	--

Form

Printed Name and Title Dan Casserly, Executive Director, Federal Government Relations

3000051645

Registrant Name Novartis Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR - Health Issues (one per page)

16. Specific lobbying issues

H.R. 2218 Regulation of non corrective contact lens as medical devises
 S.930 food and Drug Administration Safety Act of 2005
 H.R. 2090 Food and Drug Administration Improvement Act of 2005
 H.R. 3196 Fair Access to clinical Trials Act
 S. 470 FACT Act

17. House(s) of Congress and Federal agencies contacted Check if None

Senate
 House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
James	Elkin		Vice President, Federal Government Relations
Daniel	Casserly		Executive Director, Federal Government Relations
Thomas	Giles		Executive Director, Federal Government Relations
Deborah	Bumbaugh		Director, Federal Government Relations
David	Drake		Executive Director, Federal Government Relations
Sarah	Haller		Executive Director, International and Public Affai

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corp too Novartis AG, as its parent, will benefit.

Printed Name and Title Dan Casserly, Executive Director, Federal Government Relations

3000051646

Registrant Name Novartis Client Name Novartis

ADDENDUM for General Lobbying Issue Area HCR

16. Specific lobbying issues (continued from previous page)

H.R. 3428 OTC Medicine Tax Fairness Act of 2005
S.1514 OTC Medicine Tax Fairness Act of 2005

S.172 To amend the Federal Food, Drug and Cosmetic Act to provide for the regulation of all contact lenses medical devices, and for other purposes.

H.R. 371 To amend the Federal Food, Drug and Cosmetic Act to provide for the regulation of all contact lens medical devices, and for other purposes.

S.103 Combat Meth Act of 2005
H.R. 314 Combat Meth Act of 2005

S.950 Elimination of Neglected Diseases Act of 2005

H.R. 3057 Dept. of State, Foreign Operations, and Related Programs Appropriations Act, 2006

H.R. 2744 Agriculture, Rural Development, Food and Drug Admin. and Related Agencies Appropriations Act 2006

Federal Food, Drug and Cosmetic Act (Section 767)

H.R. 2051 Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act of 2005

S. 173 Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act of 2005

H.R. 5762 Contact Lens Consumer Protection Act

H.R. 5337 National Security Foreign Investment Reform and Strengthened Transparency Act of 2006

- Drug Importation
- Medicare Part B and Part D
- Sickle Cell Anemia
- Immunosuppressant Legislation
- Cancer Therapies Legislation
- Gene Therapy
- Direct to Consumer Advertising
- Medicare Prescription Drugs and Modernization Act
- Follow-on Protein Products
- Patent Law Reform
- Drug Safety Legislation
- 1-800 Contacts
- DOD Authorization Language

Add page to continue specific issues description for ti

000051647

Registrant Name Novartis Client Name Novartis

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code TRD - Trade (Domestic & Foreign) (one per page)

16. Specific lobbying issues *Add page to continue specific issues description for this issue* >

China/World Trade Organization
Free Trade Agreements
Commerce
USTR

17. House(s) of Congress and Federal agencies contacted Check if None

U.S. Agency for International Development (USAID)

18. Name of each individual who acted as a lobbyist in this issue area *Add a page to continue adding lobbyists for*

First Name	Name Last Name	Suffix	Covered Official Position (if applicable)
Sarah	Haller		<i>Vice President</i> Executive Director, International and Public Affairs
Renard	Aron		Director, Public Affairs for Latin America

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corp too Novartis AG, as its parent, will benefit.

Add a page for 3

Printed Name and Title Dan Casserly, Executive Director, Federal Government Relations

3000051648

